A detailed history of Bank Of America Corp transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 5,744 shares of CTMX stock, worth $6,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,744
Previous 77,814 92.62%
Holding current value
$6,835
Previous $169,000 95.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.21 - $5.13 $87,204 - $369,719
-72,070 Reduced 92.62%
5,744 $7,000
Q1 2024

May 15, 2024

BUY
$1.41 - $2.74 $84,649 - $164,495
60,035 Added 337.67%
77,814 $169,000
Q4 2023

Feb 14, 2024

SELL
$1.07 - $1.55 $14,426 - $20,898
-13,483 Reduced 43.13%
17,779 $27,000
Q2 2023

Aug 14, 2023

SELL
$1.41 - $1.92 $12,364 - $16,836
-8,769 Reduced 21.91%
31,262 $53,000
Q1 2023

May 12, 2023

SELL
$1.48 - $2.88 $2,927 - $5,696
-1,978 Reduced 4.71%
40,031 $60,000
Q4 2022

Feb 10, 2023

BUY
$1.19 - $1.91 $34,415 - $55,239
28,921 Added 220.97%
42,009 $67,000
Q3 2022

Nov 14, 2022

SELL
$1.23 - $1.97 $6,352 - $10,175
-5,165 Reduced 28.3%
13,088 $19,000
Q2 2022

Aug 12, 2022

BUY
$1.53 - $2.89 $5,428 - $10,253
3,548 Added 24.13%
18,253 $33,000
Q1 2022

May 16, 2022

SELL
$2.67 - $4.68 $97,193 - $170,361
-36,402 Reduced 71.23%
14,705 $39,000
Q4 2021

Feb 08, 2022

BUY
$3.87 - $7.39 $75,294 - $143,779
19,456 Added 61.47%
51,107 $221,000
Q3 2021

Nov 15, 2021

BUY
$4.32 - $6.43 $28,909 - $43,029
6,692 Added 26.81%
31,651 $161,000
Q2 2021

Sep 13, 2021

BUY
$6.33 - $9.91 $157,990 - $247,343
24,959 New
24,959 $158,000

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $78.5M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.